Cenobamate Reduces Seizure Frequency Significantly in Phase 2 Trial
In the phase 2 trial (NCT01866111) treatment with cenobamate (SK Life Science, Paramus, NJ) resulted in statistically significant greater reductions in focal seizure frequency compared with baseline. Those treated with cenobamate 100 mg, 200 mg, and 400 mg had median seizure frequency reduction of 36%, 55%, and 55%, respectively, compared with the placebo group (24%). Those doses also resulted in a 50% or more reduction in focal seizures compared with baseline during the maintenance phase (40%, 56%, and 64%) vs placebo (25%). During the maintenance phase, 4%, 11%, and 21% of participants...
